Navigation Links
Chrysalis BioTherapeutics, Inc., Receives $1.5m from the National Cancer Institute to Mitigate Radiotherapy-Induced Brain Tissue Damage
Date:9/23/2013

GALVESTON, Texas, Sept. 23, 2013 /PRNewswire/ -- Today, Chrysalis BioTherapeutics, Inc., announced receipt of a $1.5m contract from the National Cancer Institute (NCI) to continue its development of Chrysalin® to mitigate radiotherapy-induced damage to normal brain tissue. Radiotherapy is a primary tool for controlling tumor growth, yet damage to surrounding normal tissues limit the amount of radiation that can be used to kill tumors. Moreover, side-effects of radiotherapy can have long lasting effects on patients especially in the brain where radiation can affect learning, memory and physical functions. 

(Logo: http://photos.prnewswire.com/prnh/20130919/MM83393LOGO)

According to SEER Cancer Statics, nearly one in 161 people will be diagnosed with brain or nervous system cancer during their lifetime. Finding ways to mitigate damage from radiotherapy or restore neural function following radiotherapy may allow more effective cancer treatment to increase survival and improve quality-of-life for survivors.

This project is a collaboration between Chrysalis BioTherapeutics, Inc., Baylor College of Medicine (BCM), and the University of Texas Medical Branch (UTMB). Pre-clinical results indicate that Chrysalin® treatment restores radiation-damaged neural integrity and promotes neurogenesis in the hippocampus. "These effects of Chrysalin® may be very important," said Dr. Mostafa Waleed Gaber, Associate Professor at Baylor College of Medicine and Co-Director of the Small Animal Imaging Facility at Texas Children's Hospital, "especially in children where successful radiotherapy treatment of brain tumors may have life-long effects on cognitive function."

Chrysalin® is a naturally occurring regenerative peptide that is being developed by Chrysalis BioTherapeutics under world-wide license from UTMB to mitigate effects of nuclear radiation and radiotherapy.  "If we can reduce side effects of radiotherapy in the brain and other tissues, we can use more effective radiotherapy protocols to kill tumors, save lives, and improve quality-of-life." said Dr. Darrell Carney, CEO of Chrysalis BioTherapeutics, Inc.

About Chrysalis.   Chrysalis is a privately held early-clinical-stage biopharmaceutical company developing a thrombin peptide drug platform to mitigate effects of radiation, improve tissue regeneration, and treat myocardial and cardiovascular disease.  Chrysalin® was originally developed by Dr. Carney at UTMB and has been tested in human clinical trials (dermal healing and bone fracture repair) with no adverse side effects. For more information on Chrysalis visit http://www.chrysbio.com.

Media Contact: Kira Blackwell, 409-497-4083, kblackwell@chrysbio.com

This research is fully funded by the National Cancer Institute.  For more information on the NCI, visit http://www.cancer.gov/.        


'/>"/>
SOURCE Chrysalis Biotherapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
2. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
3. Senior Executives of Cytyc Corporation, and Constitution Medical, Inc., Announce the Launch of ATON PARTNERS
4. An Open Letter from Sterling Scott, CEO, GrowLife, Inc., Regarding the DOJ Position Change Regarding Marijuana
5. Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting
6. Neurotrope, Inc., Announces Reverse Merger and Completion of $21.9 Million Private Offering
7. National coordinated health care and health IT transformation event will be hosted by OCHIN, Inc., the Oregon Medical Association, and Oregon Health Network: The cHealth Innovation Symposium
8. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
9. MELA Sciences, Inc., A Leader In The Fight Against Melanoma, Hosts Symposium At 8th World Congress Of Melanoma
10. Astute Medical, Inc., veranstaltet Symposium aus anlaß des Critical Care Nephrology Kongress
11. Pioneering Medical Technology Company, Optivus Proton Therapy, Inc., Celebrates 20th Anniversary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 3, 2016  Specialty Silicone Fabricators is offering ... how a cleanroom works. The free visual aid ... and technology. Chris Mazelin ... company, SSF enthusiastically supports the Science, Technology, Engineering ... the next generation of innovators. We want to ...
(Date:5/3/2016)... Utah , May 3, 2016  Forté Elements, LLC (Forté) is excited to ... nutritional products that address the nutritional needs of recovery for a variety of clinical ... products. Photo - http://photos.prnewswire.com/prnh/20160502/362548 Logo -  http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
(Date:5/3/2016)... 2016 Norgine B.V. ... einen entscheidenden Meilenstein durch diese Veröffentlichung zur  ... Handeln, um Patientenresultate  bei Verdauungs- und Lebererkrankungen ... im Verständnis der Hepatischen Enzephalopathie bei und ... Hepatische Enzephalopathie in der Öffentlichkeit zu schaffen ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Dermatologic surgeons performed nearly 10 million medically necessary ... percent since 2012. , The results of the 2015 ASDS Survey on Dermatologic Procedures ... cancer treatments and the growing popularity of soft-tissue fillers and body sculpting procedures. ...
(Date:5/5/2016)... GA (PRWEB) , ... May 05, 2016 , ... Liposuction ... (FDRS) 2016 Conference in St. Louis, Missouri at the Marriot St. Louis Airport Hotel. ... Byrd was chosen to address the conference about her unique specialization in treating Lipedema. ...
(Date:5/5/2016)... ... 2016 , ... Augusta Public Schools has teamed with CareDox to provide confidential ... health offices to streamline and bolster care for district students. , Augusta School ... public schools serve 2,300 students among its six schools. , Monica Guilliams, BSN, ...
(Date:5/5/2016)... ... ... Dental365 in Levittown opened just a few short months ago, but is ... with the patient’s comfort and convenience in mind. Located at 3254 Hempstead Turnpike ... routine and walk-in emergency dental care 365 days a year. And now they have ...
(Date:5/4/2016)... , ... May 05, 2016 , ... “Less than 15% ... Little City Executive Director. “As one of ten non-profit organizations to participate and complete ... of Light. The ultimate benefit is that for every $1 we invest in volunteer ...
Breaking Medicine News(10 mins):